CCCC SEC Filings: 8-K, 10-Q, S-3 & 424B – C4 Therapeutics

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

C4 Therapeutics Reports Q3 2026 Financial Results and Provides Clinical Pipeline Updates

Nov 5, 2026

8-K

C4 Therapeutics Presents New Biomarker Data from Cemsidomide Trials in Multiple Myeloma at the 23rd IMS Annual Meeting

Sep 25, 2026

8-K

C4 Therapeutics Reports Q2 2026 Financial Results and Clinical Progress for Cemsidomide

Aug 11, 2026

8-K

C4 Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 24, 2026

8-K

C4 Therapeutics June 2026 Corporate Update: Advancing Targeted Protein Degradation (TPD) Pipeline

Jun 11, 2026

8-K

C4 Therapeutics Announces Departure of Chief Accounting Officer and Appointment of Successor

May 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

December 2025 ATM | Offering amount: $125,000,000 | Amount sold to date: $3,769,483

Dec 10, 2025

424B5

REGISTERED OFFERING

Oct 16, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 4,874,550

Nov 15, 2024

424B5

ATM | Offering amount: $200,000,000

Nov 15, 2024

424B4

Distributions on Our Common Stock-

Jun 21, 2021

424B4

9,600,000 Shares

Oct 2, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-3

November 2025 SHELF | Offering amount: $400,000,000

Nov 21, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Oct 16, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 4,874,550 EFFECTIVE

Oct 31, 2024

S-3

SHELF | ATM | Offering amount: $400,000,000.00 EFFECTIVE

Oct 31, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 16, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Anderson Kenneth Carl (Reporting)

Oct 2, 2026

GROGAN DONNA ROY (Reporting)

Oct 2, 2026

Adams Kendra (Reporting)

Sep 21, 2026

144

Form 144 - Report of proposed sale of securities

Aug 14, 2026

144

Form 144 - Report of proposed sale of securities

Aug 14, 2026

SCHEDULE 13G/A

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 11, 2025

CORRESP

Form CORRESP - Correspondence

Dec 8, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 14, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 14, 2024

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Nov 13, 2024

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Nov 13, 2024

C4 Therapeutics, Inc. CCCC · SEC Filings